创业慧康科技股份有限公司 董事、监事和高级管理人员持有和买卖 本公司股票管理制度 二○二四年十二月 第一章 总 则 第一条 为加强对创业慧康科技股份有限公司（以下简称"公司"或"本公 司"）董事、监事和高级管理人员所持本公司股份及其变动的管理，根据《公司 法》《证券法》和中国证券监督管理委员会（以下简称"中国证监会"）《上市 公司董事、监事和高级管理人员所持本公司股份及其变动管理规则》以及深圳证 券交易所（以下简称"深交所"）《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、监事、高级管理人员减持股份》等规定，特制定本制度。 第二条 公司董事、监事和高级管理人员所持本公司股份，是指登记在其名 下和利用他人账户持有的所有本公司股份。 公司董事、监事和高级管理人员从事融资融券交易的，其所持本公司股份还 包括记载在其信用账户内的本公司股份。 第三条 公司董事、监事和高级管理人员及本制度第七条规定的自然人、法 人或其他组织持有及买卖本公司股份的，应当遵守本制度的有关规定进行股份买 卖行为。 公司及董事、监事和高级管理人员在买卖本公司股票及其衍生品种前，应知 悉《公司法》《证券法》等法律、法规、规范性文件 ...

证券代码：300451 证券简称：创业慧康 公告编号：2024-043 创业慧康科技股份有限公司 关于持股 5%以上股东减持股份计划的预披露公告 持股 5%以上股东葛航先生保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"、"本公司"）于近日收到 持股 5%以上股东葛航先生出具的《关于股份减持计划的告知函》，现将相关事 项公告如下： 一、股东的基本情况 1、股东的名称：葛航 2、股东持股情况：截至本公告日，葛航先生持有本公司 220,519,182 股，占 本公司总股本比例 14.24%，占剔除公司回购专用账户股份后总股本比例 14.28%。 二、本次减持计划的主要内容 1、减持原因：偿还债务及利息，降低质押融资风险。 2、股份来源：公司首次公开发行前已发行的股份、发行股份购买资产非公 开发行方式获得的股份（包括资本公积金转增股本部分）。 3、减持数量：以集中竞价方式减持不超过 15,444,264 股（含），且任意连 续 90 日内减持股份的总数不超过公司股份总数的 1.00%；若此期间，公司有送 股、资本公积金转增股份变动事项，该 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price reflecting a potential upside of over 20% within the next six months [7][15]. Core Insights - The company is steadily advancing its cloud transformation strategy, leveraging data services and AI innovations to enhance its offerings [1][2]. - In Q3 2024, the company reported a revenue of 442 million yuan, a year-on-year decrease of 2.35%, and a net profit attributable to the parent company of 25 million yuan, down 62.33% year-on-year [1]. - The healthcare sector remains robust, with revenue reaching 1.12 billion yuan in the first three quarters of 2024, accounting for over 95.89% of total revenue, marking a year-on-year growth of 6.19% [2][4]. Financial Performance Summary - For the first three quarters of 2024, the company achieved total revenue of 1.169 billion yuan, a slight increase of 1.01% year-on-year, while net profit attributable to the parent company was 53 million yuan, down 42.27% year-on-year [1]. - The overall expense ratio for the first three quarters was 35.48%, a decrease of 2.96 percentage points year-on-year, with sales, management, and R&D expense ratios at 7.35%, 14.89%, and 15.87%, respectively [1]. - The company expects net profits for 2024-2026 to be 150 million, 216 million, and 305 million yuan, respectively, with corresponding P/E ratios of 60, 42, and 30 [3]. Strategic Developments - The company has signed 20 new contracts worth over 10 million yuan each in the healthcare sector and has assisted seven hospitals in passing electronic medical record evaluations [2]. - The new generation product HI-HIS is being actively promoted, with 71 ongoing projects, over 70% of which are in tertiary hospitals [2]. - The company has established a partnership with Huawei for deep collaboration on the HarmonyOS version of its healthcare app, which integrates health services in the Tongxiang area [3][5]. Market Position and Valuation - The company is recognized as one of the first information technology vendors in the healthcare sector to receive native development certification from Kunpeng [3]. - The financial projections indicate a recovery in the healthcare IT demand, with expected revenue growth rates of 11.20%, 10.60%, and 10.30% for 2024, 2025, and 2026, respectively [11].

Investment Rating - The report maintains a "Buy" rating for Chuangxin Huikang (300451 SZ) with a target price of 5 47 RMB per share [4] Core Views - Chuangxin Huikang's 2024 Q1-3 performance was under pressure due to declining gross margins and increased impairment losses The company reported revenue of 1 17 billion RMB, a 1 0% YoY increase, while net profit attributable to shareholders dropped 42 3% YoY to 52 75 million RMB [1][7] - The gross margin for 2024 Q1-3 was 50 1%, down 2 6 percentage points YoY, with Q3 gross margin at 43 45%, a 10 52 percentage point decline YoY [1][7] - The company recognized impairment losses of 43 66 million RMB in Q3 2024, a 25 0% YoY increase, mainly due to higher provisions for accounts receivable and contract assets [1][7] - The Hi-HIS product is being actively promoted, with 71 ongoing projects, over 70% of which are in tertiary hospitals The company's AI product "Medical Copilot" has received compatibility certification from Huawei's Ascend AI framework [1][13] Financial Performance - 2024 Q1-3 revenue was 1 17 billion RMB, up 1 0% YoY, while net profit attributable to shareholders was 52 75 million RMB, down 42 3% YoY [7] - Q3 2024 revenue was 440 million RMB, down 2 4% YoY, with net profit attributable to shareholders dropping 62 3% YoY to 25 38 million RMB [8] - Operating cash flow for 2024 Q1-3 was -200 million RMB, compared to -170 million RMB in the same period last year [8] - Accounts receivable increased 19 0% to 1 88 billion RMB as of September 2024, while contract liabilities decreased 3 9% to 151 million RMB [8] Product and Market Development - The Hi-HIS product is being promoted in 71 projects, with over 70% in tertiary hospitals The company expects gross margins to improve as the product matures [1][13] - The company's BSoftGPT model has been approved by the National Internet Information Office, and its AI product "Medical Copilot" has received Huawei Ascend AI framework certification [1][13] - Chuangxin Huikang is the first core medical system supplier to receive Huawei's Kunpeng native development certification and has collaborated with Huawei's HarmonyOS team to develop a native version of the Health Tongxiang app [1][13] Financial Forecasts - Revenue for 2024-2026 is projected to be 1 70 billion, 1 85 billion, and 2 00 billion RMB, respectively, with net profit attributable to shareholders expected to be 100 million, 270 million, and 330 million RMB [2][18] - EPS for 2024-2026 is forecasted at 0 06, 0 17, and 0 22 RMB per share, respectively [2][18] - The company's 2025 PE ratio is estimated at 32x, with a target price of 5 47 RMB per share [2][18] Industry and Market Position - Chuangxin Huikang is a leading player in the medical IT industry, with a strong focus on AI and healthcare information systems [1][13] - The company has established partnerships with major players like Huawei, positioning itself as a key supplier in the healthcare information technology sector [1][13]

Investment Rating - The report maintains a "Buy" rating for the company, with a market price of RMB 5.20 and a sector rating of "Outperform" compared to the market [1]. Core Views - The company is expected to benefit from the recent government policy aimed at debt reduction, which is anticipated to improve its financial statements. The policy is expected to alleviate the debt burden on local governments, enhancing the company's cash flow and receivables collection [3]. - The acceleration of public data resource marketization is expected to benefit the company, as it provides various data services across multiple fields, including clinical research and insurance underwriting [3]. - The company has established multiple collaborations with Huawei in the healthcare information sector, which is expected to enhance its technological capabilities and service offerings [3]. - The earnings per share (EPS) estimates for 2024-2026 are projected to be RMB 0.14, RMB 0.20, and RMB 0.26, respectively, with corresponding price-to-earnings (PE) ratios of 36X, 26X, and 20X [3]. Financial Summary - The company reported a revenue of RMB 1.17 billion for the first three quarters of 2024, reflecting a year-on-year growth of 1.0%. However, the net profit attributable to the parent company decreased by 42.3% to RMB 52.75 million [3]. - The projected revenue for the years 2024 to 2026 is expected to grow from RMB 1.80 billion to RMB 2.48 billion, with growth rates of 11.4%, 16.7%, and 17.9%, respectively [4]. - The net profit for the same period is projected to increase significantly from RMB 219 million in 2024 to RMB 395 million in 2026, indicating a growth rate of 498.0% in 2024 [4][6]. - The company's EBITDA is expected to rise from RMB 284 million in 2024 to RMB 449 million in 2026, reflecting a strong growth trajectory [4][6].

Investment Rating - Maintains an "Overweight" rating with a target price of 7.77 RMB [3] - Current price is 5.20 RMB, indicating potential upside [3] Core Views - Revenue and performance are expected to recover gradually as the medical informatization industry rebounds [4] - The company continues to execute its "Huikang Cloud" strategy, focusing on intelligent transformation and deepening cooperation with Huawei's HarmonyOS [4] - Despite lower-than-expected Q3 performance, the company secured 20 new orders worth over 10 million RMB each and helped 7 hospitals achieve Level 5 or above in electronic medical record system functionality [5] Financial Performance - Q3 2024 revenue was 4.4 billion RMB, a 2.4% YoY decline, while total revenue for the first three quarters reached 11.7 billion RMB, up 1.0% YoY [5] - Medical industry revenue grew 6.2% YoY to 11.2 billion RMB in the first three quarters [5] - Net profit attributable to shareholders for the first three quarters was 527.5 million RMB, down 42% YoY, with Q3 net profit at 253.8 million RMB, a 62% YoY decline [5] Strategic Developments - The company is leveraging data assets to drive AI development, with its BSoftGPT model approved by the National Internet Information Office and partnerships established with the Hangzhou AI Computing Center [5] - The company's AI product "Medical Copilot" has passed Huawei's Ascend AI framework and hardware compatibility certification, becoming the first core medical system supplier to do so [5] - The company has launched a native HarmonyOS version of the "Healthy Tongxiang" app, integrating local health and medical resources [5] Market and Valuation - The company's market cap is 8,055 million RMB, with a 52-week price range of 3.10-7.90 RMB [6] - The company's PS ratio is 4.44x for 2024E, lower than the industry average of 6.34x [12] Financial Forecasts - Revenue is expected to grow to 18.16 billion RMB in 2024E, 20.56 billion RMB in 2025E, and 23.45 billion RMB in 2026E [10] - Net profit attributable to shareholders is forecasted to increase to 1.15 billion RMB in 2024E, 1.92 billion RMB in 2025E, and 2.75 billion RMB in 2026E [10]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 6.82 [2][6]. Core Views - The company reported a revenue of RMB 1.169 billion for the first three quarters of 2024, reflecting a year-on-year growth of 1.01%, while the net profit attributable to shareholders was RMB 53 million, down 42.27% year-on-year. In Q3 2024, revenue was RMB 442 million, a decline of 2.35% year-on-year, and net profit was RMB 25 million, down 62.33% year-on-year [2]. - The company's revenue from the medical sector reached RMB 1.121 billion in the first three quarters, showing a year-on-year increase of 6.19%. Recent government debt relief measures are expected to positively impact the company's public health business. The HI-HIS product is set to accelerate its promotion in 2025, enhancing the company's coverage of high-grade hospital clients and driving order growth [2][4]. - The company has maintained good cost control, with a gross margin of 50.14% for the first three quarters of 2024, a decrease of 2.56 percentage points year-on-year. The gross margin for Q3 2024 was 43.45%, down 10.52 percentage points year-on-year, primarily due to an increase in the proportion of integrated projects [3]. Summary by Sections Financial Performance - The company achieved a revenue of RMB 1.166 billion in 2024E, with a projected growth of 3.09% compared to 2023. The net profit attributable to shareholders is expected to be RMB 194 million in 2024E, a significant increase of 428.54% compared to 2023 [7]. - The earnings per share (EPS) is projected to be RMB 0.13 in 2024E, with a return on equity (ROE) of 4.04% [7]. Product Development - The new HI-HIS product is expected to enhance the company's client structure, with over 70 ongoing projects, of which more than 70% are in tertiary hospitals. The acceleration of HI-HIS product promotion in 2025 is anticipated to significantly boost overall order growth [4]. - The company is strengthening its capabilities in medical AI and big data, with several initiatives including the BSoftGPT model and partnerships for exploring AI applications in healthcare [5]. Valuation and Forecast - The company’s net profit forecasts for 2024-2026 are adjusted to RMB 194 million, RMB 302 million, and RMB 391 million respectively. The target price is set at RMB 6.82, based on a 35 times price-to-earnings ratio [6][7].

Financial Performance - Revenue for the third quarter was RMB 441.88 million, a decrease of 2.35% year-over-year[3] - Net profit attributable to shareholders was RMB 25.38 million, a decrease of 62.33% year-over-year[3] - The company achieved a total revenue of 1.169 billion yuan in the first three quarters of 2024, with the medical industry contributing 1.121 billion yuan, accounting for over 95.89% of total revenue and a year-on-year growth of 6.19%[13] - Total revenue for the period reached 1,168,619,942.05 yuan, a slight increase from the previous period's 1,156,924,027.69 yuan[18] - Net profit attributable to the parent company's owners was 1,439,498,996.31 yuan, up from 1,402,190,565.46 yuan[17] - Net profit attributable to parent company shareholders was RMB 52.75 million, compared to RMB 91.38 million in the same period last year[19] - Basic and diluted earnings per share were both RMB 0.03, down from RMB 0.06 in the previous year[20] - Total comprehensive income was RMB 58.59 million, compared to RMB 93.40 million in the same period last year[19] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 5.82 billion, an increase of 0.54% compared to the end of the previous year[3] - Total assets stood at 5,821,824,109.65 yuan, slightly higher than the previous period's 5,790,350,720.78 yuan[17] - Total liabilities decreased to 1,106,878,023.44 yuan from 1,126,467,178.33 yuan[17] - Cash and cash equivalents decreased to 687,970,589.17 yuan from 1,094,386,640.73 yuan[15] - Accounts receivable increased to 1,880,229,204.24 yuan from 1,579,674,434.61 yuan[15] - Inventory rose to 330,841,062.94 yuan from 283,234,875.90 yuan[15] - Fixed assets increased significantly to 511,343,002.03 yuan from 303,467,328.02 yuan[15] - Total cash and cash equivalents at the end of the period were RMB 687.41 million, down from RMB 975.22 million at the beginning of the period[21] Cash Flow - Cash received from tax refunds decreased by 52.61% year-over-year, mainly due to reduced VAT refunds[8] - Cash received from other operating activities increased by 68.88% year-over-year, mainly due to increased interest income[8] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets decreased by 31.20% year-over-year, mainly due to reduced payments for the new building[8] - Cash flow from operating activities was negative RMB 201.95 million, compared to negative RMB 174.24 million in the same period last year[20] - Cash flow from investing activities was negative RMB 180.50 million, compared to negative RMB 253.63 million in the same period last year[21] - Cash flow from financing activities was negative RMB 17.57 million, compared to negative RMB 74.51 million in the same period last year[21] Investments and Expenditures - Development expenditure increased by 597.01% compared to the beginning of the year, mainly due to increased investment in new product development such as Huikang Cloud[7] - Fixed assets increased by 68.50% compared to the beginning of the year, primarily due to the completion of a new building[7] - Prepayments increased by 35.91% compared to the beginning of the year, mainly due to increased prepayments for system integration[7] - Investment income decreased by 79.68% year-over-year, mainly due to reduced investment income from associates[7] - R&D expenses increased to 185,412,536.45 yuan from 176,415,877.61 yuan in the previous period[18] Operational Highlights - The company signed 20 new orders worth over 10 million yuan each and assisted 7 hospitals in passing the electronic medical record system functional application level 5 and above review[13] - The company has 71 ongoing HI-HIS product projects, with over 70% being in tertiary hospitals[13] - The company's BSoftGPT large model has passed the "Deep Synthesis Service Algorithm" filing with the National Internet Information Office[13] - The company's subsidiary, Hangzhou Huikang Internet Technology Co., Ltd., became a member of the Guangzhou Data Exchange, promoting the development of AI industry clusters[13] - The company's AI product "Medical Copilot" passed Huawei's Ascend AI framework and hardware compatibility certification, becoming the first core medical system supplier[14] - The company is among the first in the healthcare industry to receive the Kunpeng native development certification[14] - The company completed the development and release of the native HarmonyOS version of the Health Tongxiang APP, integrating local health and medical service resources[14] Revenue and Costs - Revenue from sales of goods and services was RMB 840.34 million, compared to RMB 866.15 million in the same period last year[20] - Payments for goods and services were RMB 463.23 million, compared to RMB 454.05 million in the same period last year[20] - Payments to employees were RMB 453.68 million, compared to RMB 419.01 million in the same period last year[20] - Operating costs amounted to 1,006,634,936.64 yuan, compared to 999,878,174.97 yuan in the previous period[18]

证券代码：300451 证券简称：创业慧康 公告编号: 2024-042 创业慧康科技股份有限公司 关于 2024 年第三季度计提信用减值准备和资产减值准备 的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）根据《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》《企业会计准则》以 及公司相关会计政策的规定，在 2024 年第三季度计提了信用减值损失及资产减 值损失，现将具体情况公告如下： 一、本次计提信用减值准备和资产减值准备情况概述 1、本次计提信用减值准备和资产减值准备的原因 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》等相关规定 的要求，为真实准确地反映公司 2024 年 7 月 1 日至 2024 年 9 月 30 日的财务状 况和经营成果，公司对截止 2024 年 9 月 30 日的各类资产进行了减值测试，基于 谨慎性原则，对部分资产计提信用减值准备以及资产减值准备合计人民币 43,661,171.07 元。具体情况如下表： | | 项目 | 本期发生额（单位：元） ...

证券代码：300451 证券简称：创业慧康 公告编号：2024-040 创业慧康科技股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、审议通过了《关于补选公司第八届董事会战略与 ESG 委员会委员和提 名委员会委员的的议案》 根据《公司法》《公司章程》及公司董事会各专门委员会工作细则的有关规 定，公司第八届董事会将补选刘令女士为战略与 ESG 委员会委员，补选謝寜煒 女士为提名委员会委员，任期自本次董事会审议通过之日起至第八届董事会届满 时止。补选后战略与 ESG 委员会和提名委员会组成人员如下： （1）董事会战略与 ESG 委员会由董事张吕峥先生、董事应晶先生、董事胡 燕女士、董事刘令女士和独立董事刘海宁先生五位委员组成，其中张吕峥先生任 召集人； （2）董事会提名委员会由独立董事蔡家楣先生、独立董事凌云先生、董事 张吕峥先生、独立董事刘海宁先生和董事謝寜煒女士和五位委员组成，其中蔡家 楣先生任召集人。 表决结果：此项议案以 11 票赞同，0 票反对，0 票弃权，该议案获得通过。 特此公告。 2024 年 10 月 ...